X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs PANACEA BIOTECH - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD PANACEA BIOTECH LUPIN LTD/
PANACEA BIOTECH
 
P/E (TTM) x 29.3 -6.4 - View Chart
P/BV x 2.8 1.9 147.9% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 LUPIN LTD   PANACEA BIOTECH
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
PANACEA BIOTECH
Mar-14
LUPIN LTD/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,465149 985.2%   
Low Rs72782 883.5%   
Sales per share (Unadj.) Rs349.684.1 415.5%  
Earnings per share (Unadj.) Rs5.6-18.3 -30.4%  
Cash flow per share (Unadj.) Rs29.6-6.7 -441.5%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs300.383.7 358.8%  
Shares outstanding (eoy) m452.0861.25 738.1%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.11.4 228.4%   
Avg P/E ratio x197.2-6.3 -3,125.8%  
P/CF ratio (eoy) x37.1-17.2 -214.9%  
Price / Book Value ratio x3.61.4 264.5%  
Dividend payout %90.00-   
Avg Mkt Cap Rs m495,5027,074 7,004.2%   
No. of employees `00017.02.8 619.7%   
Total wages/salary Rs m28,6471,449 1,976.8%   
Avg. sales/employee Rs Th9,273.61,874.1 494.8%   
Avg. wages/employee Rs Th1,681.0527.0 319.0%   
Avg. net profit/employee Rs Th147.4-407.7 -36.2%   
INCOME DATA
Net Sales Rs m158,0425,154 3,066.6%  
Other income Rs m1,504100 1,506.5%   
Total revenues Rs m159,5455,254 3,036.9%   
Gross profit Rs m31,475-766 -4,107.4%  
Depreciation Rs m10,859711 1,527.2%   
Interest Rs m2,0441,503 136.0%   
Profit before tax Rs m20,076-2,881 -697.0%   
Minority Interest Rs m-7111 -656.5%   
Prior Period Items Rs m35-6 -617.5%   
Extraordinary Inc (Exp) Rs m-14,6441,771 -826.9%   
Tax Rs m2,88517 17,170.2%   
Profit after tax Rs m2,513-1,121 -224.1%  
Gross profit margin %19.9-14.9 -133.9%  
Effective tax rate %14.4-0.6 -2,463.5%   
Net profit margin %1.6-21.8 -7.3%  
BALANCE SHEET DATA
Current assets Rs m122,0953,810 3,204.4%   
Current liabilities Rs m50,9568,365 609.1%   
Net working cap to sales %45.0-88.4 -50.9%  
Current ratio x2.40.5 526.1%  
Inventory Days Days85156 54.3%  
Debtors Days Days12067 178.4%  
Net fixed assets Rs m129,87614,480 896.9%   
Share capital Rs m90461 1,475.0%   
"Free" reserves Rs m134,866903 14,933.7%   
Net worth Rs m135,7715,127 2,648.0%   
Long term debt Rs m64,2455,832 1,101.7%   
Total assets Rs m263,05419,433 1,353.6%  
Interest coverage x10.8-0.9 -1,181.1%   
Debt to equity ratio x0.51.1 41.6%  
Sales to assets ratio x0.60.3 226.5%   
Return on assets %1.72.0 88.2%  
Return on equity %1.9-21.9 -8.5%  
Return on capital %3.73.6 102.3%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m53,1411,539 3,452.5%   
Fx outflow Rs m19,335942 2,052.5%   
Net fx Rs m33,807597 5,660.9%   
CASH FLOW
From Operations Rs m17,512599 2,922.5%  
From Investments Rs m-14,073-438 3,213.7%  
From Financial Activity Rs m-14,921-303 4,930.9%  
Net Cashflow Rs m-11,482-141 8,125.8%  

Share Holding

Indian Promoters % 46.6 74.5 62.6%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 0.6 1,883.3%  
FIIs % 31.9 1.3 2,453.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 23.6 42.8%  
Shareholders   98,259 10,259 957.8%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   PLETHICO PHARMA  BIOCON LTD  J.B.CHEMICALS  NATCO PHARMA  AJANTA PHARMA  

Compare LUPIN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Dec 14, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE LUPIN LTD WITH

MARKET STATS